CME Group (NASDAQ:CME) Price Target Raised to $310.00

CME Group (NASDAQ:CME) had its price target increased by UBS Group from $270.00 to $310.00 in a report published on Thursday,Benzinga reports. UBS Group currently has a neutral rating on the financial services provider’s stock.

CME has been the subject of a number of other research reports. Wells Fargo & Company boosted their price target on CME Group from $315.00 to $333.00 and gave the stock an “overweight” rating in a research report on Thursday. TD Cowen raised their price target on CME Group from $292.00 to $300.00 and gave the company a “buy” rating in a report on Monday, October 5th. Wall Street Zen upgraded shares of CME Group from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 3rd. Weiss Ratings upgraded shares of CME Group from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, October 8th. Finally, Barclays upped their price objective on shares of CME Group from $281.00 to $321.00 and gave the stock an “equal weight” rating in a report on Thursday. Ten analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $313.29.

CME Group Stock Performance

Shares of NASDAQ CME opened at $305.71 on Thursday. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.13. The stock has a 50 day simple moving average of $277.60 and a 200-day simple moving average of $270.74. The company has a market cap of $109.93 billion, a PE ratio of 25.08, a P/E/G ratio of 3.92 and a beta of 0.24. CME Group has a 12-month low of $218.31 and a 12-month high of $329.16.

CME Group (NASDAQ:CME) last issued its quarterly earnings data on Wednesday, October 21st. The financial services provider reported $3.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.99 by $0.03. CME Group had a return on equity of 16.23% and a net margin of 63.33%. The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.71 billion. During the same period in the prior year, the company posted $2.68 EPS. The business’s revenue for the quarter was up 10.6% compared to the same quarter last year. On average, equities research analysts forecast that CME Group will post 12.35 EPS for the current year.

CME Group Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, September 25th. Shareholders of record on Wednesday, September 9th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date was Wednesday, September 9th. CME Group’s dividend payout ratio is 42.66%.

Insider Transactions at CME Group

In other CME Group news, Director Martin Gepsman sold 400 shares of the stock in a transaction on Thursday, October 22nd. The stock was sold at an average price of $302.50, for a total transaction of $121,000.00. Following the completion of the transaction, the director directly owned 25,244 shares of the company’s stock, valued at approximately $7,636,310. This trade represents a 1.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Elizabeth Cook sold 500 shares of CME Group stock in a transaction on Monday, September 14th. The shares were sold at an average price of $280.11, for a total value of $140,055.00. Following the transaction, the director owned 17,916 shares in the company, valued at approximately $5,018,450.76. This trade represents a 2.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 15,900 shares of company stock valued at $4,377,655. Company insiders own 0.30% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Brookmont Capital Management raised its position in CME Group by 0.6% in the third quarter. Brookmont Capital Management now owns 5,661 shares of the financial services provider’s stock worth $1,483,000 after acquiring an additional 34 shares in the last quarter. Manchester Capital Management LLC boosted its position in shares of CME Group by 2.9% during the 3rd quarter. Manchester Capital Management LLC now owns 1,297 shares of the financial services provider’s stock valued at $340,000 after purchasing an additional 37 shares in the last quarter. NBT Bank N A NY boosted its position in shares of CME Group by 2.3% during the 1st quarter. NBT Bank N A NY now owns 1,666 shares of the financial services provider’s stock valued at $492,000 after purchasing an additional 38 shares in the last quarter. Resonant Capital Advisors LLC boosted its position in shares of CME Group by 3.8% during the 1st quarter. Resonant Capital Advisors LLC now owns 1,073 shares of the financial services provider’s stock valued at $317,000 after purchasing an additional 39 shares in the last quarter. Finally, Grove Bank & Trust grew its stake in shares of CME Group by 0.8% in the 3rd quarter. Grove Bank & Trust now owns 5,038 shares of the financial services provider’s stock worth $1,320,000 after purchasing an additional 39 shares during the last quarter. Institutional investors own 87.75% of the company’s stock.

Trending Headlines about CME Group

Here are the key news stories impacting CME Group this week:

• Positive Sentiment: Record quarterly results: CME reported third-quarter revenue of approximately $1.74 billion, up 10.6% year over year and above the $1.71 billion consensus estimate. EPS of $3.02 also exceeded expectations of $2.99, while average daily volume reached a record 29.4 million contracts. CME third-quarter revenue article
• Positive Sentiment: Crypto derivatives momentum: CME recorded approximately $469.5 billion in crypto derivatives volume during the third quarter, highlighting growing demand for regulated digital-asset products. The company has not separately disclosed crypto revenue, so the direct earnings contribution remains unclear. CME crypto derivatives volume article
• Positive Sentiment: More bullish analyst coverage: JPMorgan upgraded CME from “underweight” to “overweight” and set a $367 price target, citing improving volume and earnings prospects. Wells Fargo also raised its target to $333. JPMorgan CME rating
• Positive Sentiment: Expansion opportunities: CME plans to launch CME Securities Clearing on December 7, potentially broadening its clearing business. Management also highlighted strong participation and international volume growth. CME Securities Clearing article
• Neutral Sentiment: Valuation remains debated: UBS lifted its price target from $270 to $310 but retained a “neutral” rating, indicating that much of the improved outlook may already be reflected in the stock. UBS CME rating
• Negative Sentiment: Insider sale: Director Martin Gepsman sold 400 shares for approximately $121,000. The transaction reduced his holdings by 1.56%, but he still owns 25,244 shares, limiting the sale’s significance. CME director stock sale

About CME Group

CME Group Inc operates global derivatives marketplaces that provide trading, clearing and settlement services for futures and options contracts. Its products cover major asset classes, including interest rates, equity indexes, foreign currencies, agricultural commodities, energy and metals. The company also provides market data, benchmark information and related services used by financial institutions, corporations, producers, investors and other market participants.

CME Group’s exchange portfolio includes CME, the Chicago Board of Trade, the New York Mercantile Exchange and COMEX.